In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

Restrictions Lifted on Aida’s Antibiotic

publication date: Oct 11, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Aida Pharmaceuticals reported that Chinese officials have loosened restrictions on Etimicin Sulfate, the company’s new generation of aminoglycoside antibiotic. Etimicin Sulfate, the first antibiotic to be developed in China, is a broad spectrum antibiotic used for serious infections. In its various forms (powder, injection, infusion), the antibiotic provides all of Aida’s revenues.  We look at the company and its main product...

Stock Symbol: (OTCBB: AIDA)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners